Journal of Managed Care & Specialty Pharmacy

Patients receiving galcanezumab had lower all-cause and migraine-related office visits over a 24-month follow-up period when compared with patients receiving standard-of-care preventive migraine treatments. Total all-cause and migraine-related costs were higher for patients receiving galcanezumab; however, patients receiving galcanezumab had lower all-cause and migraine-related costs for office visits compared with patients receiving standard-of-care treatment. Prescription cost was the main driver of total costs for patients treated with galcanezumab and standard of care. Read more in the latest edition of JMCP: https://bit.ly/4dG1xFj #healthcosts #drugpricing #healthcare #managedcae #pharmacy

A recent study set out to determine whether a pharmacy service affects total health care costs, amounts paid by individuals plus insurance. The pharmacy service is called the appointment-based model (ABM), in which pharmacists work with their patients to allow them to pick up their medications on the same day and address other medication-related issues. Total costs for patients who participated in the ABM were lower than for those matched controls who did not participate. Read more: https://bit.ly/3yTduIe #JMCP #healthcare #managedcare #pharmacy #peerreviewed

Nearly 85% of the U.S. population has prescription drug coverage through pharmacy benefits provided by public & private plans. These plans, as reported in JMCP's Managed Care Pharmacy Primer on Quality Measurement and Reporting in Pharmacy Benefit Plans, are assessed by their quality and other requirements. https://bit.ly/3xXsN1Q #JMCP #AMCPprimers

Gain valuable insights into current and evolving treatments for inherited blood disorders like hemophilia, sickle cell disease and thalassemia in JMCP. AMCP's Market Insights program convened a panel of experts from national and regional health plans, integrated health care systems, employer benefits groups, clinical experts, the Centers for Disease Control and Prevention, and patient advocacy organizations to provide strategies for managed care organizations to manage innovative treatments for inherited blood disorders, which are crucial for evaluating long-term effectiveness and safety, ongoing decision-making, and cost management. https://bit.ly/4cQEUgC #healthcare #blooddisorder #managedcare #pharmacy

Prostate cancer (PC) is the most common cancer in men, affecting 3.3 million individuals in the United States in 2020. Although most patients present with localized disease at diagnosis, 1 in 9 have PC that will eventually progress to metastasis, with a 5-year survival rate of 34.1%. Visit JMCP to review a study in which it was determined that nearly two-thirds of men who advanced from stage IV prostate cancer to stage IV castration-resistant prostate cancer received substandard treatment before progression. Following disease progression, total health care costs were 1.5 to 2 times higher, and these men used more medical services, including hospital and outpatient visits. Access this article to gain a better understanding of the real-world economic burden of prostate cancer as it worsens: https://bit.ly/4fggoai #managedcare #healthcare #pharmacy #cancer #prostate

Understanding the genetic information related to advanced non–small cell lung cancer tumors is important so that doctors can identify the best treatment approach. Explore this study in which it is suggested that the genomic testing method known as “large-panel next-generation sequencing” (LP-NGS) is more likely to identify potential genomically guided treatment options—as well as being more cost-effective than another, more limited method, called single-gene tests (SGTs). Read more in JMCP: https://bit.ly/4fgLRcs #lungcancer #treatment #healthcare #managedcare #pharmacy

The Inflation Reduction Act empowers Medicare to engage in negotiations with pharmaceutical companies to lower drug prices. In the latest edition of JMCP, discover the primary prices that Medicare will leverage to negotiate the costs of the initial 10 selected drugs, encompassing the prices currently paid by health plans after discounts. Read more: https://bit.ly/4dfqh6Z #IRA #drugcosts #healthcare #medicare #managedcare #pharmacy

Voclosporin is the first FDA–approved oral treatment for lupus nephritis (LN) in adults. This study evaluated health care plan provider costs including the use of voclosporin for managing LN in the United States. Results based on the latest evidence demonstrated that voclosporin is a cost-effective treatment. Read more: https://bit.ly/4dypfmc #healthcosts #healthcare #managedcare #pharmacy

Now Available: From evolving oncology care management trends in the United States to adherence to GLP-1 receptor agonists among obese commercially insured adults without diabetes, the August 2024 issue of JMCP is full of studies crucial to the managed care pharmacy practice. Explore the latest issue today: https://bit.ly/4difkSe #glp1 #oncology #managedcare #pharmacy

Tralokinumab is the first selective interleukin 13 inhibitor approved for moderate to severe atopic dermatitis (AD). In the July issue of JMCP, the AMCP Foundation P&T Competition first place recipients from the University of Connecticut School of Pharmacy share their findings from a comprehensive literature review and extensive economic analysis to assess tralokinumab’s safety, effectiveness, and cost. Read the article today to gain useful insight into the drug's impact on AD: https://bit.ly/3y84wqf #AMCPFdn #atopicdermatitis #healthdisparities #healthequity